<DOC>
	<DOC>NCT01361009</DOC>
	<brief_summary>This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment. Parkinson disease patients with different severity who have already used pramipexole could be observed in this study. In the whole observation period, treatment decision was determined by physician and patient completely. The safety endpoint is AE(Adverse Event), SAE(Serious Adverse Event), patient withdraw, laboratory test.</brief_summary>
	<brief_title>a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criteria: 1. Diagnosed as idiopathic PD (Parkinson' disease) according to UK brain bank criteria 2. Age: from 30 to 75 years old 3. Stage IIV of revised HoehnYahr standards 4. With current use of pramipexole 5. Informed consent signed by every subject Exclusion criteria: 1. Diagnosis of ParkinsonÂ¿s syndrome 2. Current use of psychotolytic medications 3. Allergic to pramipexole or any other ingredient of pramipexole 4. Female patients in pregnancy and lactation 5. Patients who were participating in other clinical studies by signing relevant informed consent or who received other investigational drugs within 30 days prior to the study</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>